Glucose-independent persistence of PAI-1 gene expression and H3K4 tri-methylation in type 1 diabetic mouse endothelium: Implication in metabolic memory

Biochemical and Biophysical Research Communications

Volumn 433, Issue 1, 2013, Pages 66-72

  Takizawa, Fumihiko ^a   Mizutani, Shuki ^a   Ogawa, Yoshihiro ^a   Sawada, Naoki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Endothelial dysfunction; Epigenetic mechanism; H3K4me3; Metabolic memory; PAI 1; Type 1 diabetes

Indexed keywords

GLUCOSE; HISTONE H3; LYSINE; LYSINE 4; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; PROTEIN FN1; PROTEIN ROCK2; PROTEIN SERPINE 1; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CHROMOSOME; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUCOSE BLOOD LEVEL; HISTONE METHYLATION; HYPERGLYCEMIA; IMMUNOPRECIPITATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; THROMBOSIS; UPREGULATION;

ANIMALS; CELLS, CULTURED; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; ENDOTHELIAL CELLS; EPIGENESIS, GENETIC; GENE EXPRESSION; GLUCOSE; HISTONES; HUMANS; MALE; METHYLATION; MICE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SERPIN E2;

MUS;

EID: 84875808258     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.064     Document Type: Article

References (26)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 1993, 329:977-986.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
3. Chalmers J., Cooper M.E. UKPDS and the legacy effect. N. Engl. J. Med. 2008, 359:1618-1620.
4. Kilpatrick E.S., Rigby A.S., Atkin S.L. The Diabetes control and complications trial: the gift that keeps giving. Nat. Rev. Endocrinol. 2009, 5:537-545.
5. Pirola L., Balcerczyk A., Okabe J., et al. Epigenetic phenomena linked to diabetic complications. Nat. Rev. Endocrinol. 2010, 6:665-675.
6. Kolluru G.K., Bir S.C., Kevil C.G. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int. J. Vasc. Med. 2012, 2012:918267.
7. El-Osta A., Brasacchio D., Yao D., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 2008, 205:2409-2417.
8. Brasacchio D., Okabe J., Tikellis C., et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009, 58:1229-1236.
9. Okabe J., Orlowski C., Balcerczyk A., et al. Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ. Res. 2012, 110:1067-1076.
10. Yao L., Romero M.J., Toque H.A., et al. The role of RhoA/Rho kinase pathway in endothelial dysfunction. J. Cardiovasc. Dis. Res. 2010, 1:165-170.
11. McGill J.B., Schneider D.J., Arfken C.L., et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994, 43:104-109.
12. Schneider D.J., Sobel B.E. PAI-1 and diabetes: a journey from the bench to the bedside. Diabetes Care 2012, 35:1961-1967.
13. Thogersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998, 98:2241-2247.
14. Johansson L., Jansson J.H., Boman K., et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000, 31:26-32.
15. Sawada N., Kim H.H., Moskowitz M.A., et al. Rac1 is a critical mediator of endothelium-derived neurotrophic activity. Sci. Signal 2009, 2:ra10.
16. Ehara T., Kamei Y., Takahashi M., et al. Role of DNA methylation in the regulation of lipogenic glycerol-3-phosphate acyltransferase 1 gene expression in the mouse neonatal liver. Diabetes 2012, 61:2442-2450.
17. Dahl J.A., Collas P. A rapid micro chromatin immunoprecipitation assay (microChIP). Nat. Protoc. 2008, 3:1032-1045.
18. Laufs U., Liao J.K. Targeting Rho in cardiovascular disease. Circ. Res. 2000, 87:526-528.
19. Chen S., Feng B., George B., et al. Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E127-E137.
20. Rikitake Y., Liao J.K. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 2005, 111:3261-3268.
21. Cooper M.E., El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ. Res. 2010, 107:1403-1413.
22. Reddy M.A., Natarajan R. Epigenetic mechanisms in diabetic vascular complications. Cardiovasc. Res. 2011, 90:421-429.
23. Dimova E.Y., Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb. Haemost. 2008, 100:992-1006.
24. Hou B., Eren M., Painter C.A., et al. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J. Biol. Chem. 2004, 279:18127-18136.
25. Liao H., Hyman M.C., Lawrence D.A., et al. Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha. FASEB J. 2007, 21:935-949.
26. Pekowska A., Benoukraf T., Zacarias-Cabeza J., et al. H3K4 tri-methylation provides an epigenetic signature of active enhancers. EMBO J. 2011, 30:4198-4210.